Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.22.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues From Strategic Partnerships and Other License Agreements
The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Three Months Ended June 30, Six Months Ended June 30,
  2022 2021 2022 2021
Seagen $ 2,607  $ 338  $ 2,919  $ 704 
AstraZeneca (130) 2,202  4,623  16,702 
Servier 230  745  4,964  1,512 
Genentech 991  —  2,180  — 
Total Revenue $ 3,698  $ 3,285  $ 14,686  $ 18,918 
Schedule of Potential Milestone Payments
Under the Company’s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 900  $ 4,100 
Servier 125  94 
Seagen 754  450 
Boston Pharmaceuticals 88  265 
Genentech 834  600 
Total potential milestone payments $ 2,701  $ 5,509